Sabaté M, Alfonso F, Cequier A, et al. - Among patients with ST-segment elevation myocardial infarction, researchers compared magnesium-based bioresorbable scaffold (MgBRS) vs permanent metallic sirolimus-eluting stent (SES) in terms of in-stent/scaffold vasomotion at 12-month follow-up in this investigator-driven, multicenter, randomized, single-blind, controlled trial. They randomized the participants 1:1 to SES or MgBRS at 11 academic centers. At 1 year, a higher capacity of vasomotor response to pharmacological agents (either endothelium-independent or-dependent) was displayed by MgBRS vs SES. However, lower angiographic efficacy, as well as a higher rate of target lesion revascularization, was reported in relation to MgBRS, with no thrombotic safety concerns noted.